Who are carboxymethylcellulose 0.5% +glycerin 0.9%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TheraTears® Lubricant Eye Drop, Systane Complete Preservative-Free, Hypromellose Eye Drops, Prosicca sine, Rohto Dry-Aid®, Sodium Hyaluronate Ophthalmic 0.4%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carboxymethylcellulose-0-5-glycerin-0-9.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

carboxymethylcellulose 0.5% +glycerin 0.9% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

carboxymethylcellulose 0.5% +glycerin 0.9% (carboxymethylcellulose 0.5% +glycerin 0.9%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / ocular lubricant. Area: Ophthalmology.

marketed Artificial tear / ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

carboxymethylcellulose 0.5% +glycerin 0.9% (carboxymethylcellulose 0.5% +glycerin 0.9%) — Allergan. Carboxymethylcellulose and glycerin work together to lubricate and hydrate the ocular surface, providing relief from dry eye symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
carboxymethylcellulose 0.5% +glycerin 0.9% TARGET	carboxymethylcellulose 0.5% +glycerin 0.9%	Allergan	marketed	Artificial tear / ocular lubricant
TheraTears® Lubricant Eye Drop	TheraTears® Lubricant Eye Drop	University of Waterloo	marketed	Artificial tear / Ocular lubricant
Systane Complete Preservative-Free	Systane Complete Preservative-Free	University of Waterloo	marketed	Artificial tear / Ocular lubricant
Hypromellose Eye Drops	Hypromellose Eye Drops	Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	marketed	Artificial tear / Ocular lubricant
Prosicca sine	Prosicca sine	Medical University of Vienna	marketed	Artificial tear / ocular lubricant
Rohto Dry-Aid®	Rohto Dry-Aid®	The Mentholatum Company	marketed	Artificial tear / ocular lubricant
Sodium Hyaluronate Ophthalmic 0.4%	Sodium Hyaluronate Ophthalmic 0.4%	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / ocular lubricant class)

Allergan · 2 drugs in this class
Chang Gung Memorial Hospital · 1 drug in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nguyen Viet Giap · 1 drug in this class
ORA, Inc. · 1 drug in this class
Ocusoft, Inc. · 1 drug in this class
The Mentholatum Company · 1 drug in this class
Tianjin Eye Hospital · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). carboxymethylcellulose 0.5% +glycerin 0.9% — Competitive Intelligence Brief. https://druglandscape.com/ci/carboxymethylcellulose-0-5-glycerin-0-9. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab